28.07
price up icon1.30%   0.36
after-market アフターアワーズ: 29.19 1.12 +3.99%
loading
前日終値:
$27.71
開ける:
$27.85
24時間の取引高:
973.10K
Relative Volume:
0.61
時価総額:
$1.64B
収益:
$32.87M
当期純損益:
$674.31M
株価収益率:
2.471
EPS:
11.36
ネットキャッシュフロー:
$-330.11M
1週間 パフォーマンス:
+5.65%
1か月 パフォーマンス:
-0.88%
6か月 パフォーマンス:
-20.66%
1年 パフォーマンス:
-14.45%
1日の値動き範囲:
Value
$27.10
$28.93
1週間の範囲:
Value
$26.04
$28.93
52週間の値動き範囲:
Value
$22.24
$46.00

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
名前
Agios Pharmaceuticals Inc
Name
セクター
Healthcare (1112)
Name
電話
617-649-8600
Name
住所
88 SIDNEY STREET, CAMBRIDGE, MA
Name
職員
488
Name
Twitter
@AgiosPharma
Name
次回の収益日
2024-10-31
Name
最新のSEC提出書
Name
AGIO's Discussions on Twitter

Compare AGIO vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
28.07 1.62B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
465.02 117.03B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
783.65 82.35B 14.34B 4.50B 3.77B 41.56
Biotechnology icon
ARGX
Argen X Se Adr
833.54 51.64B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
308.48 42.58B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ONC
Beone Medicines Ltd Adr
346.42 38.87B 4.98B 69.60M 525.67M 0.5198

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2025-11-24 開始されました Truist Buy
2025-11-20 アップグレード Leerink Partners Market Perform → Outperform
2025-11-19 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2025-02-24 開始されました H.C. Wainwright Buy
2024-10-16 開始されました Scotiabank Sector Outperform
2024-10-10 再開されました Raymond James Outperform
2024-09-27 ダウングレード Leerink Partners Outperform → Market Perform
2024-02-08 開始されました Cantor Fitzgerald Overweight
2023-02-03 開始されました Piper Sandler Overweight
2022-11-17 アップグレード Goldman Sell → Neutral
2022-07-27 アップグレード SVB Leerink Mkt Perform → Outperform
2021-12-03 開始されました BofA Securities Buy
2021-07-30 ダウングレード Goldman Neutral → Sell
2021-07-01 開始されました Raymond James Mkt Perform
2021-06-10 開始されました H.C. Wainwright Buy
2021-03-01 ダウングレード JP Morgan Overweight → Neutral
2021-03-01 アップグレード SVB Leerink Mkt Perform → Outperform
2021-02-26 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-10-22 アップグレード Barclays Equal Weight → Overweight
2020-03-04 開始されました Barclays Equal Weight
2019-11-26 開始されました Cantor Fitzgerald Overweight
2019-09-23 アップグレード Guggenheim Neutral → Buy
2019-05-23 再開されました Goldman Neutral
2019-02-15 アップグレード SVB Leerink Mkt Perform → Outperform
2018-09-25 開始されました Leerink Partners Mkt Perform
2018-05-23 開始されました Citigroup Buy
2018-04-11 繰り返されました Credit Suisse Outperform
2018-02-15 繰り返されました Needham Buy
2018-02-15 繰り返されました SunTrust Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2017-08-10 繰り返されました Needham Buy
2017-08-08 繰り返されました SunTrust Buy
2017-08-02 アップグレード Leerink Partners Mkt Perform → Outperform
2017-06-26 ダウングレード Janney Buy → Neutral
2017-01-17 アップグレード Oppenheimer Perform → Outperform
2016-10-24 開始されました Needham Buy
2016-06-13 アップグレード JP Morgan Neutral → Overweight
2016-05-18 繰り返されました SunTrust Buy
すべてを表示

Agios Pharmaceuticals Inc (AGIO) 最新ニュース

pulisher
05:17 AM

Agios Pharmaceuticals (AGIO) Files Automatic Mixed Securities Sh - GuruFocus

05:17 AM
pulisher
03:57 AM

Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada

03:57 AM
pulisher
02:50 AM

AGIO: HC Wainwright & Co. Raises Price Target to $65 with Buy Ra - GuruFocus

02:50 AM
pulisher
02:37 AM

Truist Securities raises Agios Pharma stock price target to $39 on pipeline progress - Investing.com Canada

02:37 AM
pulisher
02:12 AM

Agios Pharmaceuticals Inc (AGIO) Q4 2025 Earnings Call Highlight - GuruFocus

02:12 AM
pulisher
01:33 AM

Agios Pharmaceuticals (NASDAQ:AGIO) Posts Earnings Results, Beats Expectations By $0.11 EPS - MarketBeat

01:33 AM
pulisher
12:59 PM

Agios Pharmaceuticals: Early Aqvesme Traction and REMS-Driven Uptake Support Robust Mitapivat Growth and Buy Rating - TipRanks

12:59 PM
pulisher
09:43 AM

Earnings call transcript: Agios Pharm Q4 2025 sees strong revenue growth - Investing.com Canada

09:43 AM
pulisher
09:39 AM

AGIO: Strong 2025 growth, ACTIVASE launch momentum, and key pipeline catalysts set for 2026 - TradingView

09:39 AM
pulisher
09:35 AM

AGIOS PHARMACEUTICALS, INC. SEC 10-K Report - TradingView

09:35 AM
pulisher
07:40 AM

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance

07:40 AM
pulisher
07:21 AM

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Q4 2025 Revenue Beat and Narrower Loss - ChartMill

07:21 AM
pulisher
06:50 AM

Agios Pharmaceuticals: Q4 Earnings Snapshot - kare11.com

06:50 AM
pulisher
06:47 AM

Agios Pharmaceuticals: Fourth Quarter Earnings Overview - bitget.com

06:47 AM
pulisher
06:44 AM

Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times

06:44 AM
pulisher
06:41 AM

Agios Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Availability of AQVESME™ for Thalassemia - Quiver Quantitative

06:41 AM
pulisher
06:33 AM

Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q4 Revenue $20.0M, vs. FactSet Est of $12.1M - marketscreener.com

06:33 AM
pulisher
06:30 AM

Press Release: Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - 富途牛牛

06:30 AM
pulisher
Feb 11, 2026

Avoiding Lag: Real-Time Signals in (AGIO) Movement - Stock Traders Daily

Feb 11, 2026
pulisher
Feb 11, 2026

Agios Pharm set to report earnings amid thalassemia drug rollout By Investing.com - Investing.com Canada

Feb 11, 2026
pulisher
Feb 10, 2026

Analyst Upgrade: Is Agios Pharmaceuticals Inc stock showing strong momentumRate Hike & Community Supported Trade Ideas - baoquankhu1.vn

Feb 10, 2026
pulisher
Feb 09, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Feb 09, 2026
pulisher
Feb 06, 2026

Agios Pharmaceuticals (AGIO) Valuation Check After Extended Share Price Weakness - Sahm

Feb 06, 2026
pulisher
Feb 05, 2026

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz

Feb 05, 2026
pulisher
Feb 05, 2026

Agios Pharmaceuticals (AGIO) Projected to Post Earnings on Thursday - MarketBeat

Feb 05, 2026
pulisher
Feb 04, 2026

Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat

Feb 04, 2026
pulisher
Feb 03, 2026

Agios Pharmaceuticals (AGIO): Investor Outlook On A Biotech With 30.5% Upside Potential - DirectorsTalk Interviews

Feb 03, 2026
pulisher
Jan 31, 2026

Discipline and Rules-Based Execution in AGIO Response - Stock Traders Daily

Jan 31, 2026
pulisher
Jan 30, 2026

Bull Bear: Does ProShares Trust ProShares Ultra Energy stock benefit from AI growthTrade Analysis Report & Intraday High Probability Alerts - baoquankhu1.vn

Jan 30, 2026
pulisher
Jan 30, 2026

Arrowhead gains, Agios drops as drug developers end 2025 up 34% - BioWorld MedTech

Jan 30, 2026
pulisher
Jan 30, 2026

Recap Report: Is Agios Pharmaceuticals Inc stock showing strong momentumDividend Hike & Low Drawdown Investment Ideas - baoquankhu1.vn

Jan 30, 2026
pulisher
Jan 29, 2026

Agios begins U.S. launch of thalassemia drug following FDA approval By Investing.com - Investing.com Nigeria

Jan 29, 2026
pulisher
Jan 27, 2026

Swing Trade: Is Agios Pharmaceuticals Inc stock overvalued or fairly pricedMarket Risk Report & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Jan 27, 2026
pulisher
Jan 26, 2026

Aug Summary: Does Agios Pharmaceuticals Inc have a competitive edge2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn

Jan 26, 2026
pulisher
Jan 26, 2026

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - The Manila Times

Jan 26, 2026
pulisher
Jan 26, 2026

Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewswire Inc.

Jan 26, 2026
pulisher
Jan 23, 2026

BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛

Jan 23, 2026
pulisher
Jan 23, 2026

Sickle Cell Disease Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | BRL Medicine, Oryzon Genomics, GlaxoSmithKline, Agios Pharma, Beam Therapeutics, Graphite Bio, Roche - Barchart.com

Jan 23, 2026
pulisher
Jan 23, 2026

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Agios Pharma (AGIO) and Henry Schein (HSIC) - The Globe and Mail

Jan 23, 2026
pulisher
Jan 20, 2026

Is Agios Pharmaceuticals (AGIO) Offering A Compelling Entry Point After Recent Share Price Swings - Yahoo Finance

Jan 20, 2026
pulisher
Jan 19, 2026

Agios Pharmaceuticals, Inc. (AGIO): A Bull Case Theory - Finviz

Jan 19, 2026
pulisher
Jan 19, 2026

Pharma News: Will Agios Pharmaceuticals Inc face regulatory challengesWeekly Gains Report & Daily Momentum Trading Reports - baoquankhu1.vn

Jan 19, 2026
pulisher
Jan 19, 2026

What is Agios Pharmaceuticals Inc.’s market positionQuarterly Growth Report & Fast Moving Trade Plans - bollywoodhelpline.com

Jan 19, 2026
pulisher
Jan 19, 2026

Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst - MarketBeat

Jan 19, 2026
pulisher
Jan 16, 2026

A Look At Agios Pharmaceuticals (AGIO) Valuation After AQVESME FDA Approval And Commercial Launch - Sahm

Jan 16, 2026
pulisher
Jan 15, 2026

Is Agios’ AQVESME Thalassemia Launch and Sickle Cell Pathway Altering The Investment Case For Agios Pharmaceuticals (AGIO)? - Sahm

Jan 15, 2026
pulisher
Jan 15, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 15, 2026
pulisher
Jan 15, 2026

Sectors Review: Is Agios Pharmaceuticals Inc stock influenced by commodity pricesEarnings Performance Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn

Jan 15, 2026
pulisher
Jan 14, 2026

Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - MarketBeat

Jan 14, 2026
pulisher
Jan 14, 2026

Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline - MarketBeat

Jan 14, 2026
pulisher
Jan 13, 2026

Agios Pharmaceuticals outlines 2026 strategic priorities - Yahoo Finance

Jan 13, 2026

Agios Pharmaceuticals Inc (AGIO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Agios Pharmaceuticals Inc (AGIO) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Milanova Tsveta
Chief Commercial Officer
Jan 05 '26
Sale
27.02
2,872
77,601
34,793
$44.80
price up icon 1.24%
$26.75
price down icon 0.19%
$100.75
price up icon 1.93%
$105.76
price down icon 3.31%
$146.17
price down icon 1.52%
biotechnology ONC
$346.42
price down icon 1.38%
大文字化:     |  ボリューム (24 時間):